other material
confidence high
sentiment positive
materiality 0.80
Iovance reports LN-145 + pembrolizumab 42.1% ORR in ICI-naïve mNSCLC trial
IOVANCE BIOTHERAPEUTICS, INC.
- ORR of 42.1% in ICI-naïve mNSCLC; 80% in treatment-naïve, 42.9% post-chemo, 14.3% EGFR-mutated post-TKI.
- Tumor burden reduction in 76.5% of patients; durable responses deepening over time up to 15.4 months.
- No new safety signals; TEAEs consistent with NMA-LD and IL-2 regimen.
- Results support phase 3 study design for LN-145 in front-line mNSCLC.
- Cash ~$478M (post-July offering) funds into end 2024; BLA filed for lifileucel in melanoma.